Literature DB >> 16533823

HIV-1 viral load blips are of limited clinical significance.

Patricia K Lee1, Tara L Kieffer, Robert F Siliciano, Richard E Nettles.   

Abstract

Many patients on highly active antiretroviral therapy (HAART) who achieve undetectable HIV-1 RNA levels experience transient episodes of detectable viraemia or blips, suggesting there is incomplete suppression of viral replication. This raises concern that drug resistance mutations could develop and cause eventual treatment failure. However, data from recent studies indicate that most blips are actually random biological and statistical variations around a mean viral load below detectable levels (<50 copies/mL) or due to false elevations of viral load from laboratory processing artefacts. Blips are not typically associated with the development of resistance mutations and most importantly are not associated with virological or clinical failure of previously adequate HAART.

Entities:  

Mesh:

Year:  2006        PMID: 16533823     DOI: 10.1093/jac/dkl092

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  38 in total

1.  A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.

Authors:  Thomas J Scriba; Michele Tameris; Erica Smit; Linda van der Merwe; E Jane Hughes; Blessing Kadira; Katya Mauff; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Humphrey Mulenga; Marwou de Kock; Lebohang Makhethe; Esme Janse van Rensburg; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Hendrik Geldenhuys; Adrian V S Hill; Anthony Hawkridge; Gregory D Hussey; Willem A Hanekom; Helen McShane; Hassan Mahomed
Journal:  Am J Respir Crit Care Med       Date:  2012-01-26       Impact factor: 21.405

2.  HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.

Authors:  Michael R Jordan; Julie Winsett; Aileen Tiro; Vuth Bau; Rony S Berbara; Christopher Rowley; Nobel Bellosillo; Christine Wanke; Eoin P Coakley
Journal:  World J AIDS       Date:  2013-06

3.  Results of the Abbott RealTime HIV-1 assay for specimens yielding "target not detected" results by the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test.

Authors:  N Esther Babady; Jeffrey J Germer; Joseph D C Yao
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

4.  Hepatitis: Treatment failure in chronic hepatitis B.

Authors:  Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-04       Impact factor: 46.802

5.  Factors associated with high transmission risk and detectable plasma HIV RNA in HIV-infected MSM on ART.

Authors:  Jill Blumenthal; Richard Haubrich; Sonia Jain; Xiaoying Sun; Michael Dube; Eric Daar; Joel Milam; Sheldon Morris
Journal:  Int J STD AIDS       Date:  2014-01-22       Impact factor: 1.359

6.  Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era.

Authors:  Jessica S Merlin; Liyi Cen; Amy Praestgaard; Michelle Turner; Aura Obando; Craig Alpert; Sophie Woolston; David Casarett; Jay Kostman; Robert Gross; Ian Frank
Journal:  J Pain Symptom Manage       Date:  2011-11-23       Impact factor: 3.612

7.  Coamplification of HIV-1 proviral DNA and viral RNA in assays used for quantification of HIV-1 RNA.

Authors:  H Wan; A Seth; L Rainen; H Fernandes
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

8.  Measuring the HIV Care Continuum Using Public Health Surveillance Data in the United States.

Authors:  Catherine R Lesko; Lynne A Sampson; William C Miller; Jacquelyn Clymore; Peter A Leone; Heidi Swygard; Kimberly A Powers
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-15       Impact factor: 3.731

Review 9.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

10.  Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam.

Authors:  M R Jordan; H La; H D Nguyen; H Sheehan; T T M Lien; D V Duong; J Hellinger; C Wanke; A M Tang
Journal:  Int J STD AIDS       Date:  2009-06       Impact factor: 1.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.